Current press releases, talks and reports

Geneva, Dec 13, 2019 – Tumor mutational burden (TMB) is an emerging complex biomarker that is promising to be predictive for positive response to immunotherapy/checkpoint inhibitor drugs in patients diagnosed with cancer. Different approaches in testing technology made it…

Braunschweig Municipal Hospital has installed a groundbreaking process for molecular tumor analysis using next-generation sequencing (NGS). We spoke to the hospital’s medical director, Thomas Bartkiewicz, MD, and the head of the Department of Pathology, Ansgar Dellmann, MD, about…

Erlangen, May 17, 2016

• Siemens Healthcare GmbH acquires NEO New Oncology AG
  
  
• Acquisition is part of Siemens Healthineers' strategy to become a trusted and holistic partner for healthcare providers
  
  
• Siemens Healthineers will expand its portfolio with molecular testing related…

Researchers from Kantonsspital Luzern and NEO New Oncology AG publish case study on patient benefiting from comprehensive blood-based diagnostics